PMD15 Cost Utility Analysis of New Matrix Therapy Regenerating Agent (RGTA®) VS Good Wound Care for Patients with Advanced Diabetic Foot Ulcer

Abstract

Our research question was whether new Matrix Therapy ReGeneraTing Agent (RGTA®) technology is a cost-effective option for treatment of advanced diabetic foot ulcer (DFU) as an add-on therapy to good wound care (GWC) in Slovakia. Design: Health economy model, using Cost-Utility Analysis (CUA), complemented by Budget-Impact Analysis (BIA) on public health insurance coverage in Slovakia. Data sources: We have searched MEDLINE, Cochrane and available Grey literature (Industrial Sources and Expert Opinions) for meta analyses, systematic reviews, economic evaluation studies and health technology reports of treatment of DFU (until December 2018). Based on modeling, 10-years treatment costs were obtained for patients with DFU. A Markov model was created to compare the costs and effects of new Matrix Therapy RGTA® plus GWC to those of GWC alone over a 52-week period based on clinical trial data with an extension to 10-year time horizon. Health care (i.e. third-party payer’s) perspective was applied according to the Slovak methodological guidelines for economic evaluation. Cost-effectiveness is examined in 10-year time horizon. Discount rate of 5% has been used for both health gain and costs. Sensitivity analysis for major complications was implemented. Based on the given ICER threshold given by the MoH: EUR 22 896,the new Matrix Therapy RGTA® is dominant therapy compared to GWC in 10-year time horizon as well. Based on the calculations, new Matrix Therapy RGTA® for treatment of DFU is highly cost effective in comparison to GWC, furthermore new Matrix Therapy RGTA® ensures minimization of amputations in comparison to GWC alone.